VolitionRx Limited is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Henderson, NV. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2 million and a loss of $24 million (its filed statements).
Pre-revenue companyIn Vitro & In Vivo Diagnostic SubstancesHenderson, NVfilings since 19998 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2835), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.2 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.5 out of ten, present 4.7 out of ten, future 4.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 3.1 out of ten. 2 warning events since 2017; the latest 2026-04-23. 31st percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.5 out of ten. 10 filed years; profitable in 0 of 10. 35th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.6 out of ten. CrossAssetData estimate 3.6/10, confidence 35 of 100 (one part). 36th percentile among 18 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 2.2 out of ten. Leverage 596%: owes 596¢ per asset dollar. 22nd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.6 out of ten. bottom 46% of 17 in its family; net margin -1352.2%. 46th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 8.2 out of ten. top 18% of 15 in its family for leadership; chief executive since 2013. 82nd percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.4 out of ten. bottom 34% of 16 in its family for room to expand. 34th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.3 out of ten. bottom 43% of 17 in its family for growth drivers. 43rd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.6 out of ten. top 44% of 16 in its family for expectations against reality. 56th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-31 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-13 (on EDGAR). Newest filing: Form 4, 2026-09-30. Filings on record since 1999. Read from EDGAR 2026-10-12.
Who runs it
Kway, Jasmine (CEO - Singapore Volition); Reynolds, Cameron John (President and CEO); Butera, Salvatore Thomas (CEO - Volition Veterinary); Hughes, Terig (Chief Financial Officer); Gaetan, Michel (Chief Operating Officer); Forterre, Gael (Chief Commercial Officer); Micallef, Jacob Vincent (Chief Scientific Officer); Batchelor, Ann-Louise (Group Chief Marketing Officer); Retter, Andrew (Chief Medical Officer); Plummer, Nicholas (GC - Volition Diagnostics); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.